| Arcalyst — new-start gout-flare prevention |
| Prior maximum-tolerated NSAID and colchicine therapy; continue urate-lowering therapy concurrently |
| Inadequate response, intolerance, or contraindication to both NSAID and colchicine; at least two gout flares in the prior 12 months |
| Atovaquone — PCP treatment or primary prophylaxis |
| Sulfamethoxazole/trimethoprim (SMX-TMP) |
| Intolerance or contraindication to SMX-TMP; prophylaxis also requires immunocompromise |
| Brivaracetam — partial-onset seizures |
| Generic anticonvulsant; Xcopri when the patient is 18 years or older |
| Inadequate response, intolerance, or contraindication to the applicable therapy |
| Bysanti — schizophrenia or bipolar I manic/mixed episodes |
| One listed generic antipsychotic followed by one listed brand antipsychotic |
| Inadequate response, intolerance, or contraindication to both required products |
| Cabometyx — GIST |
| At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib |
| Disease progression after the prior therapies; qualifying residual, unresectable, ruptured, recurrent, or metastatic disease also required |
| Cabometyx — differentiated thyroid cancer |
| Prior VEGFR-targeted therapy; radioactive iodine therapy when applicable |
| Progression after VEGFR-targeted therapy and refractory or ineligible for radioactive iodine |
| Calcipotriene or Enstilar — plaque psoriasis |
| At least one topical corticosteroid |
| Inadequate response or intolerance, or contraindication preventing a corticosteroid trial |
| Cometriq — RET-positive NSCLC |
| Pralsetinib or selpercatinib |
| Disease progression after the prior RET-directed therapy |
| Copiktra — CLL/SLL, breast implant-associated ALCL, or peripheral T-cell lymphoma |
| Prior therapy as clinically indicated |
| Disease must be relapsed or refractory; hepatosplenic T-cell lymphoma must be refractory |
| Cresemba — invasive aspergillosis or fluconazole-refractory esophageal candidiasis in HIV |
| Voriconazole |
| Inadequate response, intolerance, or contraindication to voriconazole; oral use required |
| Dasatinib — GIST |
| Avapritinib |
| Qualifying PDGFRA exon 18 mutation and residual, unresectable, recurrent/progressive, metastatic, or tumor-rupture disease |
| Dasatinib — cutaneous melanoma |
| Prior BRAF-targeted therapy |
| Disease progression, intolerance, or risk of progression; metastatic or unresectable c-KIT-mutated disease required |
| Emsam — major depressive disorder |
| Two antidepressant classes or agents: an SNRI, SSRI, mirtazapine, or bupropion |
| Inadequate response, intolerance, or contraindication to two options; exception if unable to swallow oral formulations |
| Eprontia — focal-onset seizures |
| Generic anticonvulsant and, for adults, Xcopri |
| Inadequate response, intolerance, or contraindication to the applicable therapy |
| Eprontia or topiramate — specified generalized seizures or migraine prevention |
| Generic immediate-release topiramate |
| Prior trial required unless the patient cannot swallow solid oral dosage forms |
| Gilotrif — EGFR-positive NSCLC |
| Erlotinib, gefitinib, or osimertinib |
| Intolerable adverse event or contraindication; metastatic squamous NSCLC additionally requires progression after platinum chemotherapy |
| Fanapt — schizophrenia or bipolar I disorder |
| One listed generic antipsychotic followed by one listed brand antipsychotic |
| Inadequate response, intolerance, or contraindication to both required products |
| High-risk medications — depression indications |
| Two SSRI, SNRI, bupropion, mirtazapine, or trazodone alternatives |
| Inadequate response or intolerance to two alternatives |
| Benztropine — extrapyramidal symptoms |
| Amantadine |
| Either contraindication without a trial or inadequate response/intolerance after a trial |
| Benztropine — Parkinson disease |
| Two of amantadine, carbidopa/levodopa, pramipexole, or ropinirole |
| Inadequate response or intolerance to two alternatives |
| Guanfacine ER or hydroxyzine — anxiety |
| Two of buspirone, duloxetine, escitalopram, sertraline, or venlafaxine extended-release |
| Inadequate response or intolerance to two alternatives; acute anxiety permits an exception when two alternatives have not been tried |
| Hydroxyzine — alcohol withdrawal syndrome |
| Clorazepate or lorazepam |
| Contraindication without a trial, or inadequate response/intolerance after a trial |
| Zolpidem — insomnia |
| Doxepin 3 or 6 mg or ramelteon |
| Contraindication to both, or inadequate response/intolerance after trying one; applies to patients 65 years or older |
| Promethazine — rhinitis |
| Two of levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal |
| Inadequate response or intolerance to two alternatives |
| Iclusig — GIST |
| At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib |
| Disease progression after prior therapy; qualifying residual, unresectable, recurrent, metastatic, or tumor-rupture disease required |
| Oncology indications with specified kinase-inhibitor sequencing |
| Prior kinase inhibitors or other FDA-approved therapies specified for the requested indication |
| Resistance, intolerance, progression, or failure as specified by the indication |
| Inlurio or Itovebi — recurrent breast cancer |
| At least one line of endocrine therapy |
| Progression, relapse, or recurrence after endocrine therapy; Itovebi also requires the specified combination regimen |
| Jakafi — polycythemia vera |
| Hydroxyurea and, when applicable, Besremi |
| Inadequate response, intolerance, or resistance to hydroxyurea; also inadequate response/intolerance to Besremi or high-risk disease |
| Long-acting hydrocodone or morphine |
| Extended-release opioid for at least 30 days or immediate-release opioid for at least one week |
| Qualifying cancer, sickle-cell, terminal-condition, or palliative-care pain may qualify directly; otherwise alternatives, safe dosing, and monitoring are required |
| Lorbrena — ROS1-rearrangement-positive NSCLC |
| Crizotinib, entrectinib, repotrectinib, or taletrectinib |
| Disease progression after the prior ROS1-directed therapy |
| Lonsurf — colorectal or appendiceal adenocarcinoma |
| Prior treatment; Lonsurf must be second-line or subsequent therapy |
| Advanced or metastatic disease required |
| Lonsurf — gastric, esophageal, or gastroesophageal junction adenocarcinoma |
| At least two prior chemotherapy lines |
| Unresectable locally advanced, recurrent, or metastatic disease required |
| Megestrol acetate — adult cancer-related cachexia |
| Megestrol 40 mg/mL oral suspension |
| Inadequate response or intolerance |
| Metyrosine |
| Alpha-adrenergic antagonist |
| Inadequate response, intolerance, or contraindication |
| OpiPza — schizophrenia |
| One listed generic and one listed brand antipsychotic |
| Inability to swallow oral formulations is an alternative to both trials |
| Orserdu — recurrent breast cancer |
| Prior treatment; requested therapy is subsequent therapy |
| ER-positive, HER2-negative, ESR1-mutated advanced, recurrent, metastatic, or preoperatively unresponsive disease required |
| Pazopanib — GIST |
| At least two FDA-approved therapies, or qualifying SDH-deficient GIST |
| Disease must be residual, unresectable, recurrent/metastatic, or tumor rupture |
| Perampanel — partial-onset seizures |
| Generic anticonvulsant and, for adults, Xcopri |
| Inadequate response, intolerance, or contraindication to the applicable therapy |
| Pimecrolimus — atopic dermatitis |
| At least one first-line therapy, such as a medium- or higher-potency topical corticosteroid, when sensitive-area criteria are not met |
| Inadequate response, intolerance, or contraindication; sensitive-area disease is an alternative pathway |
| Pomalidomide — multiple myeloma |
| At least one prior therapy |
| Prior therapy is not required when the disease has CNS involvement |
| Quetiapine extended-release |
| Indication-specific generic alternatives |
| Inadequate response, intolerance, or contraindication; bipolar II depression requires immediate-release quetiapine trial or ineligibility |
| Remicade or Renflexis — rheumatoid arthritis |
| Methotrexate or a prior biologic or targeted synthetic DMARD |
| Methotrexate intolerance/contraindication or inadequate response; prior biologic/targeted synthetic DMARD failure or intolerance |
| Remicade or Renflexis — ankylosing spondylitis |
| NSAID therapy |
| Inadequate response or intolerance, or contraindication to an NSAID trial |
| Remicade or Renflexis — plaque psoriasis |
| Phototherapy, methotrexate, cyclosporine, or acitretin when severity requires prior therapy |
| At least 3% BSA with inadequate response/intolerance or contraindication; at least 10% BSA may support biologic first-line therapy |
| Qinlock — GIST |
| At least three kinase inhibitors including imatinib, or imatinib followed by sunitinib |
| Intolerance to second-line sunitinib when using the two-drug pathway |
| Rubraca — metastatic castration-resistant prostate cancer |
| Androgen receptor-directed therapy |
| BRCA-mutated disease; use with a GnRH analog or after bilateral orchiectomy |
| Rubraca — ovarian, fallopian tube, or primary peritoneal cancer maintenance |
| Prior chemotherapy |
| Stage II-IV or recurrent disease in complete or partial response to chemotherapy |
| Sorafenib — GIST |
| At least two FDA-approved therapies, such as imatinib, sunitinib, regorafenib, or ripretinib |
| Disease progression after prior therapy; qualifying residual, unresectable, ruptured, recurrent, or metastatic disease required |
| Stivarga — colorectal cancer |
| Lonsurf (trifluridine/tipiracil) |
| Advanced or metastatic disease plus inadequate response, intolerance, or contraindication to Lonsurf |
| Tadalafil — BPH |
| Alpha blocker and 5-alpha reductase inhibitor |
| Inadequate response, intolerance, or contraindication to both; erectile dysfunction is excluded |
| Temazepam — short-term insomnia |
| Doxepin 3 or 6 mg or ramelteon |
| Inadequate response, intolerance, or contraindication; applies to patients 65 years or older |
| Tafinlar — hairy cell leukemia |
| Trametinib combination |
| No prior BRAF inhibitor therapy |
| Tofacitinib — new-start inflammatory conditions |
| At least one TNF inhibitor |
| Inadequate response, intolerance, or contraindication; continuation requires beneficial response |
| Trintellix — major depressive disorder |
| One generic SNRI, SSRI, mirtazapine, or bupropion |
| Inadequate response, intolerance, or contraindication |
| Truxima — rheumatoid arthritis new start |
| Methotrexate or a prior biologic or targeted synthetic DMARD |
| Methotrexate use or intolerance/contraindication plus inadequate response, intolerance, or contraindication to methotrexate or prior DMARD |
| Ubrelvy — acute migraine |
| At least one triptan 5-HT1 receptor agonist |
| Inadequate response, intolerance, or contraindication |
| Uceris — ulcerative colitis induction |
| At least one 5-aminosalicylic acid therapy |
| Inadequate response, intolerance, or contraindication |
| Thalomid — chronic GVHD |
| Corticosteroids, azathioprine, tacrolimus, cyclosporine, or other appropriate therapies |
| Disease unresponsive to other therapies |
| Acute migraine treatment |
| At least one triptan 5-HT1 receptor agonist |
| Inadequate response, intolerance, or contraindication |
| Uceris — active mild-to-moderate ulcerative colitis |
| At least one 5-aminosalicylic acid therapy |
| Inadequate response, intolerance, or contraindication |
| Versacloz — treatment-resistant schizophrenia |
| At least one listed generic and one listed brand antipsychotic |
| Inadequate response, intolerance, or contraindication to both required products |
| Vigabatrin — complex partial seizures |
| At least two antiepileptic drugs |
| Inadequate response; age 2 years or older required for this indication |
| Wyost or Xtrenbo — hypercalcemia of malignancy |
| IV bisphosphonate therapy |
| Refractory condition or clinical reason to avoid IV bisphosphonate therapy |
| Xyrem — excessive daytime sleepiness in adults with narcolepsy |
| At least one CNS wakefulness-promoting drug, such as armodafinil or modafinil |
| Inadequate response or intolerance, or contraindication to a trial; sleep-lab-confirmed narcolepsy required |
| Zonisade — adjunctive partial-onset seizures |
| Generic anticonvulsant; Xcopri for patients 18 years or older |
| Inadequate response, intolerance, or contraindication; difficulty swallowing solid oral dosage forms is an alternative |